

**Subject: Specialised Services Circular (SSC)**

**Sent on behalf of: Chair of the SW Specialised Service Circular Group**

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

<b>SSC Number</b>	<b>SSC Title</b>	<b>Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place</b>
2883	<b>Technology Appraisal Final Draft Guidance Isatuximab plus bortezomib lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable</b>	All South West Acute Trusts

**Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? No**

**For all other South West region trusts this is for information only.**

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: [england.speccomm-southwest@nhs.net](mailto:england.speccomm-southwest@nhs.net)

**All Chief Executives**

**All Medical Directors**

**All Chief Pharmacists**

Specialised Commissioning South West  
NHS England  
100 Temple Street  
Bristol  
BS1 6AG  
Email: [england.speccomm-southwest@nhs.net](mailto:england.speccomm-southwest@nhs.net)

**12 September 2025**

Dear Colleagues,

**Re: NICE Technology Appraisal Final Draft Guidance: Isatuximab plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable.**

I am writing to advise you regarding the funding position on the recently published NICE Technology Appraisal Final Draft Guidance (FDG) for isatuximab plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable.

The FDG can be found at: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10912>.

NICE in their FDG published on 4<sup>th</sup> September 2025 has stated that:

Isatuximab plus bortezomib, lenalidomide and dexamethasone can be used, within its marketing authorisation, as an option for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.

Isatuximab will be available via the Cancer Drugs Fund (CDF) from 4<sup>th</sup> September 2025 in line with these recommendations and according to a set of treatment criteria which translates the NICE recommendation into a clinical guide as to use in practice. Bortezomib, lenalidomide and dexamethasone will be funded from routine budgets. The treatment criteria can be found on the national CDF list at <https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/> or on the application form(s) on the Blueteq site.

NHS England will then routinely commission isatuximab in patients with untreated multiple myeloma when a stem cell transplant is unsuitable, incorporating these treatment criteria, including those contained within this letter from 90 days after the day of publication of the final guidance.

In addition:


- Trusts must ensure that they are purchasing isatuximab at the agreed patient

access scheme (PAS) discounted price. This discounted price will be applied automatically at point of invoice and applies to all indications. Trusts should refer to the CAP portal for further information on the PAS price. The CAP portal is available at <https://nhsengland.sharefile.eu/Authentication/Login>

- Trusts must ensure that, until 90 days after publication of the final guidance from NICE, only invoices for the drug procurement costs of isatuximab in this indication are directed to the CDF and that they are also submitting complete and accurate information via the CDF minimum dataset (MDS).
- Trusts must ensure isatuximab is prescribed using the standardised dose bands listed in the NHS England National Dose Banding Table – isatuximab 20mg/ml - which is available at <https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-b/b02/chemotherapy-dose-banding/>
- In line with the terms and conditions included in the NHS Standard Contract and as per the agreement that Cancer Services are commissioned with Trusts, Schedule 6a Reporting Requirements for drugs will apply. Payment of Trust invoices will be contingent on the completion of the MDS record and this information being made available in a timely way.
- Trusts must ensure they are registering isatuximab use on SACT. The SACT dataset is a mandated dataset as part of the Health and Social Care Information Standards. This is listed as a Schedule 6 national information requirement within the NHS Standard Contract.
- Patients must be registered via Blueteq (ISA2) and meet the clinical criteria on the registration form during the interim funding period.
- **Payment of Trust invoices will be contingent on Blueteq registration, the full SACT and CDF MDS record applicable to the drug being completed and this information being made available in timely way.**
- Trusts must ensure that local governance aspects (e.g. technical issues, education & training, patient information) have been identified and addressed for all staff groups (as appropriate) in order to permit the safe delivery of this therapy.

I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent adoption of the policy nationally.

With best wishes



Emma Redfern  
Medical Director NHS England South West  
Region.



Tracey Williams  
Principal Pharmacist